Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
61-75 of 4028 results
Otonomy starts patient enrollment in phase 2 trial of OTO-104
Otonomy has started the enrollment of the first patients in a phase 2 clinical trial assessing OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Contract Research & Services > Clinical Trials > News
Clinigen begins US Managed Access program for TESARO’s niraparib in ovarian cancer patients
Clinigen Group's Idis Managed Access (MA) division has partnered with TESARO to launch a Managed Access program for the investigational PARP 1/2 inhibitor, niraparib.
Contract Research & Services > Clinical Trials > News
Evgen Pharma doses first patient in phase II breast cancer trial
Evgen Pharma has dosed the first patient in its Phase II clinical trial of SFX-01 in breast cancer.
Contract Research & Services > Clinical Trials > News
AstraZeneca refines endpoints in immuno-oncology trials for NSCLC
By PBR Staff Writer
AstraZeneca has refined the endpoints of its phase III clinical trial, Mystic, evaluating durvalumab and tremelimumab for first-line treatment of patients with non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Chi-Med starts phase II study of sulfatinib in second-line biliary tract cancer in China
Hutchison China MediTech (Chi-Med) has started a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.
Contract Research & Services > Clinical Trials > News
ObsEva completes phase 1 first-in-women study of OBE022 to treat preterm labor
ObsEva has completed a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2α, or PGF2α, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy.
Contract Research & Services > Clinical Trials > News
Sunovion’s dasotraline improves ADHD symptoms in children in phase 2/3 study
By PBR Staff Writer
Sunovion Pharmaceuticals’ novel drug candidate dasotraline has demonstrated significantly improved attention deficit hyperactivity disorder (ADHD) symptoms in children compared to placebo in a phase 2/3 study.
Contract Research & Services > Clinical Trials > News
Novartis to commence phase 2 trial with bimagrumab in obese patients with type 2 diabetes
MorphoSys said its partner Novartis will conduct a phase 2 clinical trial of the HuCAL antibody bimagrumab in obese patients having type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Visterra doses first patient in phase 2a trial of influenza A candidate VIS410
Visterra has dosed the first patient in the VIS410 Phase 2a clinical trial to study the monoclonal antibody for the treatment of hospitalized patients with influenza A, irrespective of the viral strain.
Contract Research & Services > Clinical Trials > News
ValiRX’s prostate cancer drug VAL201 shows positive results in Phase l/II trial
By PBR Staff Writer
ValiRx is extending its early stage trial of a prostate cancer drug, VAL201, after demonstrating disease stabilization, with a lower dose than was predicted by its preclinical evaluations.
Contract Research & Services > Clinical Trials > News
Debiopharm unveils positive phase 2 trial with Debio 1450 in ABSSSI patients
Debiopharm International has unveiled positive results from a large Phase II study of the staphylococcal-selective antibiotic Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Contract Research & Services > Clinical Trials > News
Pfizer’s Humira biosimilar shows positive top line results
By PBR Staff Writer
Results from a Reflections B538-02 study with Pfizer’s investigational Humira (adalimumab) biosimilar, PF-06410293, demonstrated that the drug met its primary endpoint, and showed same efficacy to its reference product.
Contract Research & Services > Clinical Trials > News
Seattle Genetics starts phase 1 trial of SGN-CD352A in relapsed or refractory multiple myeloma
Seattle Genetics has enrolled the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM).
Contract Research & Services > Clinical Trials > News
Ionis’ type 2 diabetes candidate shows positive results in phase 2 study
Ionis Pharmaceuticals has reported positive data from phase 2 study of IONIS-GCGR Rx in patients with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Sun Pharma’s dry eye drug Seciera demonstrates positive results in phase 3 trial
By PBR Staff Writer
Sun Pharma’s drug Seciera, indicated for the treatment of dry eye disease, has demonstrated positive results in a 12-week multicentre phase-3 clinical trial.
Contract Research & Services > Clinical Trials > News
61-75 of 4028 results